HMU cooperates with 5 foreign universities for joint medical programs. It has 4 first-grade doctorate degree programs including basic medical sciences, clinical medicine, public health and preventive medicine, and biology, 41 second-grade doctorate degree programs, and 49 second-grade master’s degree programs. There are 11 undergraduate programs. Now HMU has 5 postdoctoral research programs in preventive medicine, clinical medicine, basic medical sciences, biology and pharmacy, 1 research program in clinical pharmacy and pharmacology, and the postdoctoral research program collaborated between HMU and Zhonglong Enterprises. There are over 10,000 full-time students, among whom are over 3000 graduate students.
HMU has a reasonable discipline structure. There are 1 national key discipline, 32 provincial key disciplines, 1 incubation base of national key laboratories in biomedicine jointly established by the ministry and the province, 6 key laboratories of the ministry and the province, and 11 provincial key laboratories of higher education. Positions are available for national specially-invited professors and provincial specially-invited professors.
HMU has a number of excellent faculty members. There are now over 10,000 faculty and staff, with a well-structured combination of different ages. Of those is one academician of Chinese Academy of Engineering and one Nightingale Prize winner. Over 70 faculty members have been granted various prizes such as Chinese Outstanding Young Teacher Award, Wu Jieping Medical Research Award, and Paul Jassen Award in Pharmacy.
HMU has made remarkable scientific achievements. Significant breakthroughs have been made in China Human Genome Project, cytogenetically research on solid tumor, basic and clinical research on series of spleen preservation operation, experiment and clinical application of homogeneous in situ heart transplantation, research on the best target of antiarrhythmic drugs and etiology of Kaschin-Beck disease. In order to make full use of HMU resources, HMU cooperates with some enterprises, e.g. the Pharmaceutical R&D Center between HMU and Harbin Pharmaceutical Group, to facilitate the transformation of pharmaceutical technology to new products and lead the pharmaceutical industry at the northeastern old industrial base to rapid development. Since 2000, HMU has been granted 3 second-class awards of National Scientific and Technological Progress, 3 second-class awards of National Natural Science, over 240 research achievement awards of the ministry and the province. HMU has undertaken over 250 projects of the national Project“973”, Project “863”, and key projects of National Natural Science Foundation.HMU boasts advanced clinical technology. The five medical schools (affiliated hospitals) are ranked at top level, of which 3 are listed among the “100 best hospitals” in China. There are over 5000 beds, 2 million outpatients and over 200 thousand inpatients per year. Allogeneic organ transplantation is a distinctive feature of HMU. Allogeneic spleen transplantation, allogeneic both hands transplantation and allogeneic single forearm transplantation have reached international level. The patient who received the allogeneic heart transplantation enjoys the best life quality in Asia. The combined treatment of large intestine cancer is well-known in China. There are 2905 beds in the other 4 non-affiliated clinical hospitals.
